Herein, we describe the expression of survivin/BIRC5 and XIAP in ET, PV, and PMF patients and JAK2V617F cell lines and the molecular and cellular effects of treatment with YM155 in MPN cellular models. The gene discussed is BIRC5; the disease is myeloproliferative disorder.